Intuitive Surgical shares dropped as much as 13% in after-market trading after the company reported the slowest growth in da Vinci surgical robot procedure volume in four years. Management held its 2026 procedure growth guidance at 13.5% to 15.5% and set a non-GAAP gross margin target of 68% to 69%, offering no upward revision to offset the disappointment. Concerns about potential Affordable Care Act coverage changes and GLP-1 weight-loss drugs reducing demand for elective surgeries are weighing on the growth outlook.
A 13% after-hours drop in a mega-cap medical device stock signals that investors are repricing the growth premium baked into ISRG's valuation. If ACA coverage narrows and GLP-1 drugs continue reducing obesity-linked surgical conditions, the addressable procedure pool shrinks, which directly pressures the revenue model that justifies ISRG's historically high price-to-earnings multiple. Broader medtech ETFs like IHI hold meaningful ISRG exposure and will likely feel the drag at the open.
April 24: Full Q1 2025 Intuitive Surgical earnings call transcript and analyst Q&A. May 6-7: Next FOMC meeting, which sets the rate environment that affects hospital capital spending. Ongoing: Congressional budget reconciliation process that will determine ACA subsidy and Medicaid scope.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief